Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Cancer therapy

Advancing combination therapy for recurrent glioblastoma

Nature Medicine volume 29, pages 1318–1319 (2023)Cite this article

Subjects

Adding an oncolytic virus to classic immune checkpoint inhibition elicits treatment responses and survival benefit for select immunologically ‘cold’ recurrent glioblastomas, although creative treatment strategies are still needed for patients with highly anti-inflammatory tumors.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Oncolytic virus activity.

References

  1. Reardon, D. A. et al. JAMA Oncol. 6, 1003–1010 (2020).

    Article  PubMed  Google Scholar 

  2. Lim, M. et al. Neuro Oncol. 24, 1935–1949 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Omuro, A. et al. Neuro Oncol. 25, 123–134 (2023).

    Article  PubMed  Google Scholar 

  4. Nassiri, F. et al. Nat. Med. https://doi.org/10.1038/s41591-02347-y (2023).

    Article  PubMed  Google Scholar 

  5. Moehler, M. H. et al. Hum. Gene Ther. 16, 996–1005 (2005).

    Article  CAS  PubMed  Google Scholar 

  6. Lang, F. F. et al. J. Clin. Oncol. 36, 1419–1427 (2018).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Ribas, A. et al. Cell 170, 1109–1119 (2017).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Lu, Y. et al. Nat. Commun. 12, 4031 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Vogelbaum, M. A. et al. Neuro Oncol. 22, 1568–1579 (2020).

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurosurgery, Stanford University School of Medicine, Stanford, CA, USA

    Adela Wu & Michael Lim

Authors
  1. Adela Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael Lim
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael Lim.

Ethics declarations

Competing interests

M.L. receives research support from Arbor, BMS, Accuray, Biohaven and Urogen; is a research consultant for VBI, InCephalo Therapeutics, Merck, Pyramid Bio, Insightec, Biohaven, Sanianoia, Hemispherian, Novocure, Noxxon, InCando, Century Therapeutics, CraniUs, MediFlix and XSense; is a shareholder of Egret Therapeutics; has patents for focused radiation plus checkpoint inhibitors, local chemotherapy plus checkpoint inhibitors, and checkpoints for neuro-inflammation; is a non-research consultant for Stryker; and is on the Data Safety and Monitoring Board for Cellularity.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wu, A., Lim, M. Advancing combination therapy for recurrent glioblastoma. Nat Med 29, 1318–1319 (2023). https://doi.org/10.1038/s41591-023-02350-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41591-023-02350-3

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer